Product
DARA SC
1 clinical trial
1 indication
Indication
Multiple MyelomaClinical trial
A Phase 1 Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2017-11-01